Neuren logo

Annual Report 2007

Now available
› Download (PDF, 0.56MB)

Welcome to Neuren

A novel and dynamic biopharmaceutical company developing human therapies for neuroprotection, metabolic disease and growth-related disorders.


Recent announcements

6 August 2008
Appendix 3B 6 Aug 2008


6 August 2008
Neuren raises minimum of $3 million


6 August 2008
Share Purchase Plan offer announced


› View more announcements

Neuren Pharmaceuticals Limited is a biopharmaceutical company developing drugs for brain injury and neurodegeneration. The drugs target acute indications of brain injury such as cognitive impairment resulting from cardiac surgery and traumatic brain injury, as well as chronic conditions such as Parkinson’s and Alzheimer’s diseases. Neuren is also engaged in research and development in metabolic disorders such as cancers related to the functions of growth hormone.

Neuren has four lead candidates; Glypromate®, Motiva™ and NNZ-2566 presently in clinical development to treat four different neurological conditions, and NNZ-2591 in preclinical development for Parkinson’s disease dementia and other chronic neurodegenerative conditions.

Neuren has operations in New Zealand (Auckland based head office), Australia and the United States, and is listed on the Australian Securities Exchange (ASX: NEU).

    ©2008 Neuren Pharmaceuticals Limited